Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Nanjing Leads Biolabs Co., Ltd. Class H ( (HK:9887) ) has shared an update.
Nanjing Leads Biolabs Co., Ltd. has entered into an exclusive global license agreement with Dianthus Therapeutics, Inc. to advance LBL-047, a novel anti-BDCA2-TACI bispecific fusion protein. This agreement grants Dianthus exclusive global rights to research, develop, and commercialize LBL-047 outside Greater China, with Nanjing Leads Biolabs receiving up to $38 million in upfront and near-term milestone payments, and potential additional payments up to $1 billion. This partnership is expected to enhance the company’s position in the autoimmune disease treatment market and benefit its shareholders.
The most recent analyst rating on (HK:9887) stock is a Buy with a HK$80.27 price target. To see the full list of analyst forecasts on Nanjing Leads Biolabs Co., Ltd. Class H stock, see the HK:9887 Stock Forecast page.
More about Nanjing Leads Biolabs Co., Ltd. Class H
Nanjing Leads Biolabs Co., Ltd. is a joint stock company based in China, focusing on the biotechnology industry. The company specializes in developing innovative drug candidates, particularly targeting autoimmune diseases, and aims to advance these candidates into clinical settings.
Average Trading Volume: 1,723,948
For an in-depth examination of 9887 stock, go to TipRanks’ Overview page.